Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy, with immuno-oncology mouse models at the helm of available research tools. Major pharmaceutical companies in the world have devoted great efforts to developing cancer immunity-related treatment methods, with clinical trial results showing that treatment efficacy is very high. Furthermore, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.
Immune-checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or turn down (inhibitory molecules) immune signals. Tumors can use these checkpoints to protect themselves from immune system attacks, particularly by T cells. Checkpoint therapy can block inhibitory checkpoints or activate stimulatory molecules, restoring immune system function. In recent years, immune-checkpoint drugs have become an important novel cancer treatment, as well as immuno-oncology mouse models. Biocytogen has generated and validated a series of humanized immune-checkpoint mice that can serve as immuno-oncology mouse models for in vivo efficacy evaluation of human immune-checkpoint drug candidates.
Key features of Biocytogen’s humanized immune-checkpoint mice:
- Pure C57BL/6 genetic background leads to more consistent and reliable experimental results. Biocytogen’s humanized immune-checkpoint mice are developed using the C57BL/6 genetic background, which is commonly used in oncology, physiology, immunology and genetics studies.
- Our humanized mice are carefully designed and generated to maintain biological functions and ensure more reliable drug validation. Biocytogen has developed a wealth of experience in animal model development, with specific experience in humanized immuno-oncology mouse model design. Our experts fully consider all factors that may interfere with the expression of humanized proteins and design a detailed, scientifically accurate plan to ensure sufficient humanization, humanized protein expression, and intact signal transduction. With humanized mice, in vivo efficacy evaluation of humanized immune-checkpoint antibodies or inhibitors becomes even more reliable and dependable.
Triple Humanized Immune-checkpoint Mice
Single Humanized Immune-checkpoint Mice
Product | Product No | Background |
---|---|---|
B-HLA-A2.1 Mice | 110110 | C57BL/6N |
B-dPD-1 mice | 110022 | C57BL/6N |
B-h4-1BB mice | 110004 | C57BL/6J |
B-hAMHR2 mice | 111143 | C57BL/6N |
B-hAXL mice | 110908 | C57BL/6J |
B-hB7-H3 mice | 110028 | C57BL/6 |
B-hB7-H4 mice | 110045 | C57BL/6J |
B-hBCMA mice | 110899 | C57BL/6N |
B-hBST2 mice | 112095 | C57BL/6N |
B-hBTLA mice | 110005 | C57BL/6N |
B-hCD147 mice | 110995 | C57BL/6N |
B-hCD155 mice | 110759 | C57BL/6J |
B-hCD16A mice | 111173 | C57BL/6N |
B-hCD16A mice(CB-17 SCID) | 111174 | CB-17 SCID |
B-hCD180 mice | 111221 | C57BL/6N |
B-hCD2 mice | 111132 | C57BL/6N |
B-hCD20 mice | 111231 | C57BL/6N |
B-hCD200 mice | 111133 | C57BL/6J |
B-hCD200R mice | 111131 | C57BL/6N |
B-hCD22 mice | 110775 | C57BL/6J |
B-hCD226 mice | 110869 | C57BL/6N |
B-hCD248 mice | 111059 | C57BL/6N |
B-hCD27 mice | 110006 | C57BL/6J |
B-hCD28 mice | 110007 | C57BL/6N |
B-hCD33 mice | 110823 | C57BL/6J |
B-hCD36 mice | 111045 | C57BL/6 |
B-hCD37 mice | 110856 | C57BL/6N |
B-hCD39 mice | 110783 | C57BL/6J |
B-hCD3E mice | 110008 | C57BL/6J |
B-hCD3EDG mice | 110039 | C57BL/6J |
B-hCD4 mice | 110842 | C57BL/6J |
B-hCD40 mice | 110009 | C57BL/6N |
B-hCD40L mice | 110756 | C57BL/6J |
B-hCD43 mice | 110892 | C57BL/6N |
B-hCD44 mice | 110961 | C57BL/6J |
B-hCD45 mice | 110973 | C57BL/6J |
B-hCD47 mice | 110010 | C57BL/6N |
B-hCD47 mice(C) | 110615 | Balb/c |
B-hCD5 mice | 111125 | C57BL/6N |
B-hCD52 mice | 110860 | C57BL/6N |
B-hCD6 mice | 111145 | C57BL/6N |
B-hCD70 mice | 110770 | C57BL/6J |
B-hCD73 mice | 110027 | C57BL/6J |
B-hCD79B mice | 111096 | C57BL/6N |
B-hCD80 mice | 110935 | C57BL/6J |
B-hCD89 mice | 110864 | C57BL/6N |
B-hCD93 mice | 111135 | C57BL/6N |
B-hCD94 mice | 110044 | C57BL/6J |
B-hCD98HC mice | 110983 | C57BL/6N |
B-hCEACAM1 mice | 111073 | C57BL/6J |
B-hCLEC14A mice | 112049 | C57BL/6N |
B-hCSF1 mice | 110799 | C57BL/6J |
B-hCSF2RB mice | 110735 | C57BL/6J |
B-hCTLA4 mice | 110011 | C57BL/6N |
B-hEPCAM mice | 110826 | C57BL/6J |
B-hFAP mice | 110831 | C57BL/6J |
B-hFGL1 mice | 110116 | C57BL/6J |
B-hGARP mice | 110102 | C57BL/6J |
B-hGAS6 mice | 110985 | C57BL/6J |
B-hGITR mice | 110012 | C57BL/6N |
B-hGPC3 mice | 110873 | C57BL/6N |
B-hITGA5 mice | 111254 | C57BL/6J |
B-hITGB7 mice | 111246 | C57BL/6N |
B-hLAG3 mice plus | 110025 | C57BL/6J |
B-hLIGHT mice | 110944 | C57BL/6N |
B-hLRRC33 mice | 110757 | C57BL/6J |
B-hMCAM mice | 111168 | C57BL/6N |
B-hMERTK mice | 111278 | C57BL/6N |
B-hNKG2A mice | 110041 | C57BL/6N |
B-hNKG2D mice | 111188 | C57BL/6N |
B-hNKP46 mice | 111946 | C57BL/6J |
B-hNTRK1 mice | 110810 | C57BL/6J |
B-hOX40 mice | 110014 | C57BL/6N |
B-hPD-1 mice | 110003 | C57BL/6N |
B-hPD-1 mice Plus | 110019 | C57BL/6N |
B-hPD-L1 mice | 110015 | C57BL/6N |
B-hPDGFRB mice | 111317 | C57BL/6N |
B-hPDPN mice | 111099 | C57BL/6N |
B-hPSGL-1 mice | ||
B-hPVRIG mice | 110091 | C57BL/6J |
B-hRAGE mice | 111107 | C57BL/6N |
B-hRANKL mice | 111072 | C57BL/6J |
B-hROBO4 mice | 111022 | C57BL/6N |
B-hSELP mice | 110836 | C57BL/6J |
B-hSIGLEC10 mice | 110843 | C57BL/6N |
B-hSIGLEC15 mice | 110121 | C57BL/6N |
B-hSIRPA mice | 110016 | C57BL/6N |
B-hSRB1 mice | 111115 | C57BL/6J |
B-hTFR1 mice | 110861 | C57BL/6J |
B-hTGFBR2 mice | 110874 | C57BL/6N |
B-hTIGIT mice | 110017 | C57BL/6N |
B-hTIM3 mice | 110018 | C57BL/6N |
B-hTIM4 mice | 110837 | C57BL/6J |
B-hTLR2 mice | 111228 | C57BL/6N |
B-hTLR8 Mice | 110104 | C57BL/6J |
B-hTLR9 mice | 110103 | C57BL/6J |
B-hTREM1 mice | 111180 | C57BL/6N |
B-hTREM2 mice | 111176 | C57BL/6J |
B-hTROP2 mice | 110966 | C57BL/6N |
B-hVEGFR2 mice | 110113 | C57BL/6J |
B-hVSIG4 mice | 111035 | C57BL/6N |
B-hVSIR mice | 110049 | C57BL/6N |
B-hα4β7 mice | 111913 | C57BL/6 |
Double Humanized Immune-checkpoint Mice
Tetra Humanized Immune-checkpoint Mice
Product | Product No | Background |
---|---|---|
B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice | 112332 | C57BL/6 |
B-hPD-1/hPD-L1/hNKG2A/hCD94 mice | 111848 | C57BL/6 |
B-hPD-1/hPD-L1/hSIRPA/hCD47 mice | 140577 | C57BL/6 |
B-hPD-1/hPD-L1/hTIGIT/hPVRIG mice | 141337 | C57BL/6 |
B-hSIRPA/hCD47/hCD3E/hCD28 mice | 111874 | C57BL/6 |
Product | Product No | Background | Application |
---|---|---|---|
B-Tg(hLILRB1-hLILRB4) mice | 110878 | C57BL/6N | |
B-Tg(hLILRB2-hLILRB3) mice | 110858 | C57BL/6N | |
B-hCD16A mice(C.B6) | |||
B-hCXCL13/hCXCR5 mice | |||
B-hGPC3 CT26.WT | 322261 | BALB/c | B-hGPC3 CT26.WT cells have the capability to establish tumors in vivo and can be used for efficacy studies. |
B-hIL12A/hIL12B/hIL12RB1/hIL12RB2/hPD-1/hPD-L1 mice | |||
B-hKLB mice | |||
Tara test product 2 | 102 | test 2 | test 2 |
Tara test product 5 | 105 | test1 | test5 |